9/3/2014 8:51:03 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company’s board of directors. Together the significant insights and expertise of these two industry leaders will help to guide BIND’s management team in the achievement of its business and development goals.
Eric K. Rowinsky, M.D., currently serves as Head of Research and Chief Medical Officer at Stemline Therapeutics and as a board member of Biogen Idec Inc. and was formerly Executive Vice President of Clinical Development and Regulatory at ImClone Systems. Amy W. Schulman is the Chief Executive Officer of Arsia Therapeutics and a Venture Partner at Polaris Partners. She is the former Executive Vice President and General Counsel of Pfizer Inc. and served as the Business Unit Lead for Pfizer’s Consumer Healthcare business, after serving as President of the Nutrition Business, which was sold to Nestle for $11.85 billion.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by